Navigation Links
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Date:5/30/2008

temsirolimus may provide further evidence of clinical utility in advanced RCC," says Brian Rini, M.D., of the Cleveland Clinic Taussig Cancer Institute in Cleveland, and co-principal investigator of INTORACT.

RCC will account for approximately 85 percent of the estimated 54,390 new cases of kidney cancer that will be diagnosed in the United States annually, and about 40 percent of these patients will have advanced disease at the time of diagnosis. Clear-cell RCC accounts for about 75 percent of all RCC cases.

Wyeth is conducting a number of studies examining TORISEL in various settings. Additional information about TORISEL studies is available at http://www.clinicaltrials.gov.

About TORISEL

TORISEL is the only approved cancer therapy that specifically inhibits the mTOR kinase, an important regulator of cell proliferation, cell growth and cell survival. Inhibition of mTOR in treated cancer cells blocked the translation of genes that regulate the cell cycle. In in vitro studies using renal cancer cell lines, TORISEL inhibited the activity of mTOR and resulted in reduced levels of certain cell growth factors involved in the development of new blood vessels, such as vascular endothelial growth factor.

TORISEL is approved for the treatment of advanced RCC in the United States, European Union and other markets, based on results of a phase 3 clinical study that demonstrated that TORISEL improves overall survival for patients with advanced RCC compared with interferon-alfa.

Important Safety Information

Hypersensitivity reactions manifested by symptoms, including, but not limited to anaphylaxis, dyspnea, flushing, and chest pain have been observed with TORISEL. Serum glucose, serum cholesterol, and triglycerides should be tested before and during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
2. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
3. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
4. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
5. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
8. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
9. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
10. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an ... its third quarter of fiscal 2014: For the ... of $1,291,378, a 13% decrease over the same period of ... of $240,156 compared to net income of $238,826 during the ... the nine months ended June 30, 2014: , ...
(Date:8/27/2014)... DALLAS , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty ... data on the Fatty Liver Disease clinical trial scenario. ... the clinical trials on Fatty Liver Disease . ... their recruitment status as per the site of trial ... coverage of disease clinical trials by their phase, trial ...
(Date:8/27/2014)... Aug. 27, 2014 Ambit Biosciences (Nasdaq: AMBI ... drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, ... Care Conference to be held at The New York Palace ... September 3-4, 2014. Alan Fuhrman , Ambit,s ... lead drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5Ambit Announces Participation At Baird 2014 Health Care Conference 2
(Date:8/27/2014)... August 27, 2014 Catalent, the ... development solutions for drugs, biologics and consumer health ... privately held Australian biomarker research company, Minomic International ... (ADC) for prostate cancer therapy. Under the agreement, ... clinical study with a view to larger scale ...
(Date:8/27/2014)... August 27, 2014 Bedros Keuilian is the ... the world, the leading fitness boot camp marketing expert ... Rescue reality series. One thing he knows very well is ... subject matter expert in the fitness business. , In his ... lays out a step-by-step instructional guide on how fitness boot ...
(Date:8/27/2014)... DISCcert has scheduled its Online ... 10th, 17th, 24th, and Oct 1st from 11am-12pm PST. ... certification seal that will allow them to train staff ... four weekly one-hour webinar sessions. In between each session, ... individual coaching time. , Trainers, participating in the ...
(Date:8/27/2014)... When a friend invited Misty Mozejko to join a fitness ... beginning of a new way of life and a new career. ... knew I needed to turn my life around but I just ... stuck with the program. “It was so difficult,” she laughs. “It ... comfort zone, but between the boot camp and some good nutritional ...
(Date:8/27/2014)... 27, 2014 Helix House, an Internet ... Internet marketers reports record demand for marketing services that ... of businesses across the country and throughout Arizona looking ... they are increasingly turning to experienced Internet marketing firms ... belt, Helix House features a dedicated and organized team ...
Breaking Medicine News(10 mins):Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 3Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 2Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 3Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 4Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 3Health News:Helix House Reports Record Demand For Marketing Services That Take Advantage Of Social Media 2Health News:Helix House Reports Record Demand For Marketing Services That Take Advantage Of Social Media 3
... Group, Inc. (NYSE Amex: QGP ) ( ... Stock Transfer and Trust Company to act as Transfer Agent ... CEO, commented, "Continental Stock Transfer has been in business for ... as a comprehensive and customer-centric company that can facilitate the ...
... NETworks to get on the map. , ... Washington, ... a worldwide fundraiser challenge today to raise money to send lifesaving ... number one killer of refugees. Supporters are holding hundreds of fundraisers ...
... leading provider of strategic workforce management consulting and implementation services, ... to accommodate the firm,s growing base of healthcare clients striving to ... advanced workforce management solutions. , ... Denver, CO (PRWEB) ...
... holiday fast approaching, tons of chocolate will soon be consumed. Dr. Dave ... chocolate and which is healthier for you. , ... (PRWEB) March 31, ... Easter Bunnies are unleashed on the world; given as sweet treats for ...
... Helps Determine Benefits Included in a New Law and Manages Applicants, ... Company (NYSE: IBM ), today announced that ... Castilla y Leon region in Spain, will be helping its citizens ... through the use of a new system built around IBM ILOG ...
... N.C. A recent discovery by researchers at Wake Forest ... new drug that inhibits tumor growth in cancer patients and ... discovery stems from a study, recently published in the ... United States of America, in which researchers looked at angiogenesis ...
Cached Medicine News:Health News:The Quantum Group Announces Transition to Continental Stock Transfer 2Health News:The Quantum Group Announces Transition to Continental Stock Transfer 3Health News:Nothing But Nets Launches World Malaria Day Fundraising Challenge 2Health News:Nothing But Nets Launches World Malaria Day Fundraising Challenge 3Health News:Director of Healthcare Solutions Appointed to Guide Workforce Management Initiatives for Hospitals and Long Term Care Facilities 2Health News:Director of Healthcare Solutions Appointed to Guide Workforce Management Initiatives for Hospitals and Long Term Care Facilities 3Health News:Poison Dressed as an Easter Bunny 2Health News:Spain's Junta De Castilla y Leon Streamlines Benefits Delivery for Dependent Care With IBM ILOG JRules 2Health News:Blood protein may hold key to stopping tumor growth in cancer patients 2
... The 1000 plate capacity MG-1000 ... workstations. Two people working side by ... in those labs that need it. ... colony counter inside for real-time growth ...
... is the most versatile orthopedic/trauma ... designed for both lower body ... an integrated shoulder attachment. The ... operating table for your most ...
... 1700 Series Outpatient Surgical Table is built ... Skytron's other specialty and general purpose surgical ... features such as 180-degree top rotation for ... side rails will accommodate a wide variety ...
... The schaerer axis ... been specially designed for ... maximum C-arm access. The ... possibilities and the offset ...
Medicine Products: